Caris Life Sciences, Inc. (CAI)

Caris Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-68.09	-281.89	-341.42	-320.83
Depreciation & Amortization	22.62	48.91	49	48.25
Stock-Based Compensation	70.01	18.64	15.24	22.9
Other Adjustments	91.75	-1.8	8.2	-13.78
Change in Receivables	-29.79	-33.82	-15.08	-11.91
Changes in Inventories	-20.75	5.46	-4.44	-11.1
Changes in Accounts Payable	11.04	-0.23	7.17	8.91
Changes in Accrued Expenses	11.48	0.8	1.26	-6.6
Changes in Other Operating Activities	-5.1	-1.29	3.96	-1.56
Operating Cash Flow	83.16	-245.2	-276.1	-285.71
Capital Expenditures	-16.26	-8.44	-22.32	-42.26
Purchases of Investments	-	-	-63.4	-378.38
Proceeds from Sale of Investments	-	61.38	300.49	137.65
Investing Cash Flow	-16.26	52.93	214.77	-282.99
Long-Term Debt Issued	27.87	199.98	191.31	-
Long-Term Debt Repaid	-	-	-180	-
Net Long-Term Debt Issued (Repaid)	27.87	199.98	11.31	-
Issuance of Common Stock	536.1	1.53	1.87	11.41
Repurchase of Common Stock	-18.66	-	-	-
Net Common Stock Issued (Repurchased)	517.43	1.53	1.87	11.41
Issuance of Preferred Stock	121.24	-	-	-
Net Preferred Stock Issued (Repurchased)	121.24	-	-	-
Other Financing Activities	-1.55	-1.22	-3.04	-0.96
Financing Cash Flow	664.99	200.29	10.13	10.45
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.13	-0	0.06	0
Net Cash Flow	732.01	8.02	-51.13	-558.25
Free Cash Flow	66.9	-253.64	-298.42	-327.96
FCF Margin	8.24%	-61.53%	-97.48%	-126.88%
Free Cash Flow Per Share	0.40	-7.15	-8.54	-9829.27
Levered Free Cash Flow	-37.21	-133.06	-416.58	-325.18
Unlevered Free Cash Flow	48.13	-211.9	-284.92	-320.11

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q